MX2021007142A - Compuestos organicos. - Google Patents

Compuestos organicos.

Info

Publication number
MX2021007142A
MX2021007142A MX2021007142A MX2021007142A MX2021007142A MX 2021007142 A MX2021007142 A MX 2021007142A MX 2021007142 A MX2021007142 A MX 2021007142A MX 2021007142 A MX2021007142 A MX 2021007142A MX 2021007142 A MX2021007142 A MX 2021007142A
Authority
MX
Mexico
Prior art keywords
methods
organic compounds
methoxymethy
pregnan
anxiolytics
Prior art date
Application number
MX2021007142A
Other languages
English (en)
Spanish (es)
Inventor
Peng Li
Kimberly Vanover
Robert Davis
Yupu Qiao
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2021007142A publication Critical patent/MX2021007142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2021007142A 2018-12-17 2019-12-17 Compuestos organicos. MX2021007142A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862780703P 2018-12-17 2018-12-17
PCT/US2019/066923 WO2020131918A1 (en) 2018-12-17 2019-12-17 Organic compounds

Publications (1)

Publication Number Publication Date
MX2021007142A true MX2021007142A (es) 2021-08-11

Family

ID=71100855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007142A MX2021007142A (es) 2018-12-17 2019-12-17 Compuestos organicos.

Country Status (11)

Country Link
US (1) US12325726B2 (cg-RX-API-DMAC7.html)
EP (1) EP3897656A4 (cg-RX-API-DMAC7.html)
JP (1) JP7645797B2 (cg-RX-API-DMAC7.html)
KR (1) KR102931436B1 (cg-RX-API-DMAC7.html)
CN (1) CN113226326B (cg-RX-API-DMAC7.html)
AU (1) AU2019406803B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011765A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121636A1 (cg-RX-API-DMAC7.html)
IL (1) IL283960B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007142A (cg-RX-API-DMAC7.html)
WO (1) WO2020131918A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US12325726B2 (en) 2018-12-17 2025-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
US20230416300A1 (en) * 2020-08-20 2023-12-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2023159094A2 (en) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
DK1038880T3 (da) 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
DK2168585T3 (da) * 2005-06-09 2012-02-27 Euro Celtique Sa Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US20170233433A1 (en) * 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US12325726B2 (en) 2018-12-17 2025-06-10 Intra-Cellular Therapies, Inc. Organic compounds
US20230416300A1 (en) 2020-08-20 2023-12-28 Intra-Cellular Therapies, Inc. Organic compounds

Also Published As

Publication number Publication date
IL283960B2 (en) 2025-09-01
AU2019406803A1 (en) 2021-07-08
US20220073558A1 (en) 2022-03-10
BR112021011765A2 (pt) 2021-08-31
IL283960A (en) 2021-07-29
EP3897656A4 (en) 2022-09-21
IL283960B1 (en) 2025-05-01
JP2022513933A (ja) 2022-02-09
CN113226326A (zh) 2021-08-06
KR20210105934A (ko) 2021-08-27
US12325726B2 (en) 2025-06-10
CA3121636A1 (en) 2020-06-25
KR102931436B1 (ko) 2026-02-25
WO2020131918A1 (en) 2020-06-25
CN113226326B (zh) 2024-09-20
EP3897656A1 (en) 2021-10-27
AU2019406803B2 (en) 2025-04-24
JP7645797B2 (ja) 2025-03-14

Similar Documents

Publication Publication Date Title
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
JOP20190269A1 (ar) بولي نوكليوتيدات aadc لعلاج مرض باركنسون
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2018004755A (es) Entrega de polinucleotidos dirigidos al sistema nervioso central.
MX2022003323A (es) Polinucleotidos dirigidos al sistema nervioso central.
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
TN2016000238A1 (en) Tricyclic compounds as anticancer agents.
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
MY195948A (en) Allosteric Modulators of Nicotinic Acetylcholine Receptors
IN2014DN09804A (cg-RX-API-DMAC7.html)
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2012009079A (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2018004220A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
IL308994A (en) Compositions and methods for administering therapeutic oligonucleotides to the central nervous system
ZA202000028B (en) Use of vibegron to treat overactive bladder
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
CA2864606C (en) Methods of treating and preventing diseases and disorders of the central nervous system